OptimizeRx Corporation
Rank #109Op. LeverageOPRX · Nasdaq · Healthcare
OptimizeRx Corporation (OPRX) — Rank #109 by gross profitability (GP/assets 0.45) · ROE 3.9% · Piotroski F-Score 8 / 9.
As-of 2026-09-15 · CIK 0001448431 · all metrics point-in-time as of the filing date.
About
OptimizeRx Corporation operates as a digital healthcare technology company.
Show moreShow less
It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers' target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail. The company also offers pharmacy alerts, which flag pharmacies that have prescription medications in stock; and financial messaging solutions, which provide prescribers visibility to branded copay offers for patients directly within electronic health record systems and ePrescribing platforms.
The company was founded in 2006 and is headquartered in Waltham, Massachusetts.
- Industry
- Health Information Services
- Sector
- Healthcare
- State
- NV
- Filer Category
- Non-accelerated filerSmaller reporting company
- Fiscal Year End
- December 31
- Website
- optimizerx.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-03-12 | 2024-12-31filed 2025-03-20 | 2023-12-31filed 2024-04-15 | 2022-12-31filed 2023-03-10 |
|---|---|---|---|---|
| Assets | ||||
| Cash & equivalents | 23.4 | 13.4 | 13.9 | 18.2 |
| Short-term investments | 0.0 | — | — | 55.9 |
| Accounts receivable | 37.8 | 38.2 | 36.3 | 22.2 |
| Total current assets | 64.7 | 54.0 | 54.3 | 98.6 |
| Property, plant & equipment, net | 0.1 | 0.2 | 0.1 | 0.1 |
| Goodwill | 70.9 | 70.9 | 78.4 | 22.7 |
| Intangible assets (excl. goodwill) | — | — | — | — |
| Total assets | 176.9 | 171.2 | 183.4 | 134.7 |
| Liabilities | ||||
| Accrued liabilities | 11.6 | 8.5 | 7.8 | 2.6 |
| Deferred revenue | 0.5 | 0.5 | 0.2 | 0.2 |
| Total current liabilities | 21.3 | 18.7 | 17.9 | 8.4 |
| Total debt | 25.7 | 32.8 | 36.2 | — |
| Total liabilities | 48.6 | 54.2 | 56.8 | 8.5 |
| Equity | ||||
| Retained earnings | (79.2) | (84.4) | (64.3) | (46.7) |
| Total shareholders' equity | 128.3 | 117.0 | 126.6 | 126.1 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?